Centogene

Diagnostics revenues were €32.5 million in Q3, up almost fivefold from €6.8 million last year, and included €27.4 million from commercial coronavirus testing.

The study, called TRAMmoniTTR, will longitudinally monitor the clinical status of both symptomatic and asymptomatic participants with variants in the TTR gene.

News items for the week of Nov. 23, 2020.

The German diagnostics firm expects more than €80 million in 2020 revenues, driven by its recovering core business and its COVID-19 testing business.

Centogene will provide its oropharyngeal swabs and conduct RT-PCR testing, while U-Diagnostics will collect samples and report the results.

The tests are designed to detect viral nucleic acid in various respiratory specimens including nasal swabs, nasal aspirate, and bronchoalveolar lavage.

Revenues have begun to recover in Q3, driven by a ramp in SARS-CoV-2 testing, and the firm now expects full-year 2020 revenues to exceed its prior guidance.

The firms will combine real-life data sets in rare diseases with expertise in big data, artificial intelligence, and computational algorithms.